文献速递淋巴瘤

快速基因分型panel辅助诊断原发性中枢神经系统淋巴瘤

A rapid genotyping panel for detection of primary central nervous system lymphoma.
PubMed 文献 · Blood · 2021-01-01

研究分析1007例疑似PCNSL患者的临床评估,并设计快速多重基因分型检测MYD88、TERT启动子、IDH1/2、H3F3A和BRAF突变,以辅助从CSF诊断PCNSL及鉴别其他肿瘤。在159例确诊PCNSL患者中,中位确诊时间10天(范围0-617天)。靶向基因分型在86例存档标本中检测血液恶性肿瘤敏感性57.6%、特异性100%,在132例标本中检测恶性肿瘤标志突变敏感性65.8%、特异性100%。

要点

  • PCNSL诊断常需脑活检,CSF分析诊断率仅13.3%。
  • 靶向基因分型可快速检测MYD88、TERT启动子等突变。
  • 80分钟内可从CSF中检出PCNSL和胶质母细胞瘤的标志突变。

核心结论

  • 靶向基因分型可作为快速、可扩展的辅助手段,减少PCNSL诊断和治疗延迟。

研究设计与样本

  • 研究纳入1007例疑似PCNSL患者进行临床评估,并设计快速多重基因分型检测MYD88、TERT启动子、IDH1/2、H3F3A和BRAF突变。
  • 在86例存档临床标本和132例标本中验证检测性能,并前瞻性检测PCNSL和胶质母细胞瘤患者CSF DNA。

主要发现

  • 159例确诊PCNSL患者中位确诊时间10天,范围0至617天。
  • 152例活检中永久组织病理确诊PCNSL 142例(93.4%),113份CSF采样中仅15份(13.3%)具诊断性。
  • 86例存档标本中靶向基因分型检测血液恶性肿瘤敏感性57.6%、特异性100%(95%CI 44.1%-70.4%和87.2%-100%)。
  • 132例标本中检测恶性肿瘤标志突变敏感性65.8%、特异性100%(95%CI 56.2%-74.5%和83.9%-100%)。
  • PCNSL患者CSF DNA中MYD88突变和胶质母细胞瘤患者CSF DNA中TERT启动子突变均可在80分钟内前瞻性检出。

临床怎么用

  • 对疑似PCNSL患者,靶向基因分型可快速辅助从CSF诊断PCNSL并鉴别其他肿瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diagnosing primary central nervous system lymphoma (PCNSL) frequently requires neurosurgical biopsy due to nonspecific radiologic features and the low yield of cerebrospinal fluid (CSF) studies. We characterized the clinical evaluation of suspected PCNSL (N = 1007 patients) and designed a rapid multiplexed genotyping assay for MYD88, TERT promoter, IDH1/2, H3F3A, and BRAF mutations to facilitate the diagnosis of PCNSL from CSF and detect other neoplasms in the differential diagnosis. Among 159 patients with confirmed PCNSL, the median time to secure a diagnosis of PCNSL was 10 days, with a range of 0 to 617 days. Permanent histopathology confirmed PCNSL in 142 of 152 biopsies (93.4%), whereas CSF analyses were diagnostic in only 15/113 samplings (13.3%). Among 86 archived clinical specimens, our targeted genotyping assay accurately detected hematologic malignancies with 57.6% sensitivity and 100% specificity (95% confidence interval [CI]: 44.1% to 70.4% and 87.2% to 100%, respectively). MYD88 and TERT promoter mutations were prospectively identified in DNA extracts of CSF obtained from patients with PCNSL and glioblastoma, respectively, within 80 minutes. Across 132 specimens, hallmark mutations indicating the presence of malignancy were detected with 65.8% sensitivity and 100% specificity (95% CI: 56.2%-74.5% and 83.9%-100%, respectively). This targeted genotyping approach offers a rapid, scalable adjunct to reduce diagnostic and treatment delays in PCNSL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gupta M, Burns EJ, Georgantas NZ, et al. A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood. 2021. PMID: 33735913. doi:10.1182/blood.2020010137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。